Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag Lifevantage Corporation 27/12 17,850 USD
-2,99% 		-2,99%

Nieuws over “Farmaceutische Producten: Generisch”

23/12 · Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference · Persbericht

23/12 · Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference · Persbericht

20/12 · Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 · Persbericht

17/12 · Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease · Persbericht

11/12 · Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients · Persbericht

6/12 · Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan · Persbericht

4/12 · Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial · Persbericht

26/11 · Form 8.3 - [BENCHMARK HOLDINGS PLC - 25 11 2024] - (CGAML) · Persbericht

26/11 · Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference · Persbericht

8/11 · Teva to Present at the Jefferies London Healthcare Conference · Persbericht

6/11 · Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS · Persbericht

1/11 · Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition · Persbericht

1/11 · Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone) · Persbericht

1/11 · Europese Commissie legt farmabedrijf Teva boete op van 463 miljoen euro · Tijd.be (€)

De Europese Commissie oordeelt dat de Israëlische medicijnenmaker Teva het patentsysteem misbruikte en roddelde om een rivaal van zijn multiplescleroseblockbuster stokken in de wielen te steken. Teva ...

31/10 · Teva krijgt boete van bijna 500 miljoen euro voor misleiding rond MS-medicijn · Nu.nl

Farmaceut Teva heeft een EU-boete van 462,6 miljoen euro opgelegd gekregen. Het bedrijf zou de verkoop van een MS-medicijn van een concurrent hebben gehinderd door misleidende informatie te verspreiden.

31/10 · Teva Statement on European Commission Decision; Company to Appeal · Persbericht

22/10 · Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) · Persbericht

8/10 · Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA · Persbericht

3/10 · Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate · Persbericht

1/10 · Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. · Persbericht

30/09 · Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024 · Persbericht

Mijn selecties